Enoxaparin as bridging anticoagulant treatment in cardiac surgery

Heart

Volumn 94, Issue 2, 2008, Pages 205-210

  Rivas Gandara N ^a   Ferreira Gonzalez I ^b   Tornos Mas, P ^b   Torrents, A ^b   Permanyer Miralda, G ^b   Nicolau, I ^b   Arellano Rodrigo, E ^b   Vallejo, N ^c   Igual, A ^b   Soler Soler, J ^b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ENOXAPARIN; HEPARIN; ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART SURGERY; HIGH RISK PATIENT; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MUSCLE HEMATOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGISTER; RETROPERITONEAL HEMORRHAGE; RISK ASSESSMENT; THROMBOCYTOPENIA; THROMBOEMBOLISM; AGED; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; METHODOLOGY; MIDDLE AGED; PEROPERATIVE CARE; POSTOPERATIVE COMPLICATION; THORAX SURGERY; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; COHORT STUDIES; ENOXAPARIN; FEMALE; HEMORRHAGE; HUMANS; INTRAOPERATIVE CARE; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; THORACIC SURGICAL PROCEDURES; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 38749102016     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2006.109967     Document Type: Article

References (27)

1. DunnAS. Perioperative management of oral anticoagulation: when and how to bridge.J Thromb Thrombolysis2006;21:85-9.
2. DunnAS, TurpieAG. Perioperative management of patients receiving oral anticoagulants: a systematic review.Arch Intern Med2003;163: 901-8.
3. LongstrethJR, BernickC, FitzpatrickA, et al. Frequency and predictors of stroke death in 5888 participants in the Cardiovascular Health Study.Neurology2001;56:368-75.
4. MartinelliJ, JimenezA, RabagoG, et al. Mechanical cardiac valve thrombosis: is thrombectomy justified?. Circulation1991; 84(Suppl 3):70-5.
5. BonowRO, CarabelloB, ChatterjeeK, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons.J Am Coll Cardiol2006;48:e1-148.
6. BonowRO, CaribelloB, de LeonAC, et al. ACC/AHA guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association. Task Force on Practice Guidelines (Comittee on Management of Patients withValvular Heart Disease).J Am Coll Cardiol1998;32;1486-588.
7. SpandorferJ. The management of anticoagulation before and after procedures.Med Clin North Am2001;85:1109-16.
8. HeitJA. Perioperative management of chronically anticoagulated patient.J Thromb Thrombolysis2001;12:81-7.
9. DouketisJD. Perioperative anticoagulation management in patients who are receiving oral anticoagulant therapy: a practical guide for clinicians.Thromb Res2002;108:3-13.
10. AnsellJ, HirshJ, DalenJ, et al. Managing oral anticoagulant therapy.Chest2001;119(Suppl):22-38S.
11. DouketisJD, CrowtherMA, CherianS, et al. Physician preferences for perioperative anticoagulation in patients with a mechanical heart valve who are undergoing elective non-cardiac surgery.Chest1999;116:1240-6.
12. JeffreyIW. Low-molecular-weight heparins.N Engl J Med1997:337:688-95.
13. FanikosJ, TsilimingrasK, KucherN, et al. Comparison of efficacy, safety and cost of low molecular-weight heparin with continuous-infusion unfractionated heparin for initiation of anticoagulation after mechanical prosthetic valve implantation.Am J Cardiol2004; 93:247-50.
14. Gohlke-BärwolfC. Anticoagulation in valvular heart disease: new aspects and management during non-cardiac surgery.Heart2000; 84:567-72.
15. WarketinTE, LevineMN, HishJ, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.N Engl J Med1995;332:1330-5.
16. CarterCJ, KeltonJG, HirshJ, et al. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits.Blood1982;59;1239-45.
17. MonrealM, LafozE, OliveA, et al. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin.Thromb Haemost1994;71;7-11.
18. Asell JE. The perioperative management of warfarin therapy.Arch Intern Med2003;163:881-3.
19. SpyropoulosAC, FrostFJ, HurleyJS, et al. Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy.Chest2004;125;1642-50.
20. SpandorferFM, LynchS, WeitzH, et al. Use of enoxaparin for the chronically anticoagulated patient before and after procedures.Am J Cardiol1999;84:478-80.
21. Ferreiral, DosL, TornosP, et al. Experience with enoxaparin in patients with mechanical heart valves who must withhold acenocumarol. Heart2003;89:527-30.
22. TinmouthAH, MorrowBH, Cruickshank, et al. Dalteparin as periprocedure anticoagulation for patients on warfarin and at high risk of thrombosis.Ann Pharmacother2001;35:669-74.
23. KovacsMJ, KearonC, RodgerM, et al. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation2004;110:1518-9.
24. DouketisJD, JohnsonJA, TurpieAG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standarized periprocedural anticoagulation regimen.Arch Intern Med 2004;164:1319-26.
25. JafriSM. Periprocedural thromboprophylaxis in patients receiving chronic anticoagulation thrapy.Am Heart J2004;147:3-15.
26. MontalescotG, PolleV, ColletJP, et al. Low molecular weight heparin after mechanical heart valve replacement.Circulation2000;101:1083-6.
27. MeurinP, TavetJY, WeberH, et al. Low-molecular-weight heparin as a bridging anticoagulant early after mechanical heart valve replacement.Circulation2006;113:564-9.